S. 1096 · 119th Congress · Health

Preserve Access to Affordable Generics and Biosimilars Act

Bill aims to preserve access to affordable generics and biosimilars, but summary unavailable. AI-read

Out of committee6.7k words Introduced Mar 24, 2025 · Latest action Apr 10, 2025

How far it has goneStage 3 of 6
  1. IntroducedMar 24, 2025 Done
  2. CommitteeReported Apr 10, 2025 Done
  3. Senate floorAwaiting vote Current stage
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.

An agreement is exempt if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a U.S. patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.

The bill provides for enforcement by the Federal Trade Commission (FTC). Violators are subject to penalties including the forfeiture of the 180-day marketing exclusivity period for a generic drug.

Additionally, when a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC and the Department of Justice concerning the agreement contains the complete agreement and any related agreements, including descriptions of any oral agreements or representations.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 24, 2025

Who lobbies on it

18 organizations · 109 filings · Q1 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 7 of 7 quarters
    “S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent…”

    Q3 2026 filing · $26.6M lobbying spend in 2026 to date, all issues

  2. America's Health Insurance Plans Inc (ahip) 7 of 7 quarters
    “H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic…”

    Q3 2026 filing · $11.3M lobbying spend in 2026 to date, all issues

  3. Novartis 7 of 7 quarters
    “S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in…”

    Q3 2026 filing · $6.2M lobbying spend in 2026 to date, all issues

15 more organizations, every filingPROUpgrade

Organizations that named S. 1096 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

5 actions · newest first
  1. Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
  2. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
  3. Apr 3, 2025Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Mar 24, 2025Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
  1. Mar 24, 2025Introduced in Senate

What members said about it

  • Statement · Press release · Apr 3, 2025 · Durbin D-IL

    Senate Judiciary Committee Advances Six Bipartisan Bills To Lower Prescription Drug Prices

    This morning, the U.S. Senate Judiciary Committee advanced six bipartisan bills to help lower the price of prescription drugs.

    “Families are struggling to afford their medications. Congress must take an all-options approach to lowering prescription drug prices, and the bills we advanced today embody that spirit. The legislative package will improve coordination between agencies, bring generic drugs to market more quickly, and foster competition…”